Literature DB >> 19201410

On the mechanism for PPAR agonists to enhance ABCA1 gene expression.

Masaki Ogata1, Maki Tsujita, Mohammad Anwar Hossain, Nobukatsu Akita, Frank J Gonzalez, Bart Staels, Shogo Suzuki, Tatsuya Fukutomi, Genjiro Kimura, Shinji Yokoyama.   

Abstract

Expression of ATP binding cassette transporter A1 (ABCA1), a major regulator of high density lipoprotein (HDL) biogenesis, is known to be up-regulated by the transcription factor liver X receptor (LXR) alpha, and expression is further enhanced by activation of the peroxisome proliferator activated receptors (PPARs). We investigated this complex regulatory network using specific PPAR agonists: four fibrates (fenofibrate, bezafibrate, gemfibrozil and LY518674), a PPAR delta agonist (GW501516) and a PPAR gamma agonist (pioglitazone). All of these compounds increased the expression of LXRs, PPARs and ABCA1 mRNAs, and associated apoA-I-mediated lipid release in THP-1 macrophage, WI38 fibroblast and mouse fibroblast. When mouse fibroblasts lacking expression of PPAR alpha were examined, the effects of fenofibrate and LY518674 were markedly diminished while induction by other ligands were retained. The PPAR alpha promoter was activated by all of these compounds in an LXR alpha-dependent manner, and partially in a PPAR alpha-dependent manner, in mouse fibroblast. The LXR responsive element (LXRE)-luciferase activity was enhanced by all the compounds in an LXR alpha-dependent manner in mouse fibroblast. This activation was exclusively PPAR alpha-dependent by fenofibrate and LY518674, but nonexclusively by the others. We conclude that PPARs and LXRs are involved in the regulation of ABCA1 expression and HDL biogenesis in a cooperative signal transduction pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201410      PMCID: PMC2790138          DOI: 10.1016/j.atherosclerosis.2009.01.008

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  31 in total

Review 1.  Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?

Authors:  Philip J Barter; Kerry-Anne Rye
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-08-23       Impact factor: 8.311

2.  Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner.

Authors:  Reijiro Arakawa; Norimasa Tamehiro; Tomoko Nishimaki-Mogami; Kazumitsu Ueda; Shinji Yokoyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-03-24       Impact factor: 8.311

Review 3.  Assembly of high-density lipoprotein.

Authors:  Shinji Yokoyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-11-10       Impact factor: 8.311

4.  PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.

Authors:  G Chinetti; S Lestavel; V Bocher; A T Remaley; B Neve; I P Torra; E Teissier; A Minnich; M Jaye; N Duverger; H B Brewer; J C Fruchart; V Clavey; B Staels
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

5.  A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis.

Authors:  A Chawla; W A Boisvert; C H Lee; B A Laffitte; Y Barak; S B Joseph; D Liao; L Nagy; P A Edwards; L K Curtiss; R M Evans; P Tontonoz
Journal:  Mol Cell       Date:  2001-01       Impact factor: 17.970

6.  Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.

Authors:  Mohammad Anwar Hossain; Maki Tsujita; Frank J Gonzalez; Shinji Yokoyama
Journal:  J Cardiovasc Pharmacol       Date:  2008-03       Impact factor: 3.105

Review 7.  Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins.

Authors:  A R Tall
Journal:  J Intern Med       Date:  2008-03       Impact factor: 8.989

Review 8.  Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.

Authors:  Bart Staels; Michel Maes; Alberto Zambon
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-07-15

9.  ApoA-I facilitates ABCA1 recycle/accumulation to cell surface by inhibiting its intracellular degradation and increases HDL generation.

Authors:  Rui Lu; Reijiro Arakawa; Chisato Ito-Osumi; Noriyuki Iwamoto; Shinji Yokoyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-10       Impact factor: 8.311

10.  PPARalpha gene expression is up-regulated by LXR and PXR activators in the small intestine.

Authors:  Jun Inoue; Shin-Ichi Satoh; Mariko Kita; Mayuko Nakahara; Satoshi Hachimura; Masaaki Miyata; Tomoko Nishimaki-Mogami; Ryuichiro Sato
Journal:  Biochem Biophys Res Commun       Date:  2008-04-28       Impact factor: 3.575

View more
  38 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Lycopene Inhibits Smoke-Induced Chronic Obstructive Pulmonary Disease and Lung Carcinogenesis by Modulating Reverse Cholesterol Transport in Ferrets.

Authors:  Jelena Mustra Rakic; Chun Liu; Sudipta Veeramachaneni; Dayong Wu; Ligi Paul; C-Y Oliver Chen; Lynne M Ausman; Xiang-Dong Wang
Journal:  Cancer Prev Res (Phila)       Date:  2019-06-08

3.  Interaction of PPARG Pro12Ala with dietary fat influences plasma lipids in subjects at cardiometabolic risk.

Authors:  Aseel AlSaleh; Sandra D O'Dell; Gary S Frost; Bruce A Griffin; Julie A Lovegrove; Susan A Jebb; Thomas A B Sanders
Journal:  J Lipid Res       Date:  2011-09-23       Impact factor: 5.922

Review 4.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

5.  Tri-m-cresyl phosphate and PPAR/LXR interactions in seabream hepatocytes: revealed by computational modeling (docking) and transcriptional regulation of signaling pathways.

Authors:  Francesco Alessandro Palermo; Paolo Cocci; Matteo Mozzicafreddo; Augustine Arukwe; Mauro Angeletti; Graziano Aretusi; Gilberto Mosconi
Journal:  Toxicol Res (Camb)       Date:  2015-12-18       Impact factor: 3.524

6.  Peroxisome proliferator-activated receptor-α activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway.

Authors:  Kazuhiro Nakaya; Junichiro Tohyama; Snehal U Naik; Hiroyuki Tanigawa; Colin MacPhee; Jeffrey T Billheimer; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-24       Impact factor: 8.311

Review 7.  Insulin resistance, hyperglycemia, and atherosclerosis.

Authors:  Karin E Bornfeldt; Ira Tabas
Journal:  Cell Metab       Date:  2011-11-02       Impact factor: 27.287

Review 8.  PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty.

Authors:  Janice V Huang; Clifford R Greyson; Gregory G Schwartz
Journal:  J Lipid Res       Date:  2012-06-08       Impact factor: 5.922

9.  A novel gene regulator, pyrrole-imidazole polyamide targeting ABCA1 gene increases cholesterol efflux from macrophages and plasma HDL concentration.

Authors:  Akiko Tsunemi; Takahiro Ueno; Noboru Fukuda; Takayoshi Watanabe; Kazunobu Tahira; Akira Haketa; Yoshinari Hatanaka; Sho Tanaka; Taro Matsumoto; Yoshiaki Matsumoto; Hiroki Nagase; Masayoshi Soma
Journal:  J Mol Med (Berl)       Date:  2014-01-25       Impact factor: 4.599

10.  Mitofusin2 decreases intracellular cholesterol of oxidized LDL-induced foam cells from rat vascular smooth muscle cells.

Authors:  Chao He; Ying Chen; Chun Liu; Ming Cao; Yu-Jin Fan; Xiao-Mei Guo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.